<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850849</url>
  </required_header>
  <id_info>
    <org_study_id>LP0083-1011</org_study_id>
    <nct_id>NCT01850849</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream</brief_title>
  <official_title>A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data
      when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic
      dermatitis and to healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and change from baseline in vital signs (blood pressure, pulse rate) ECG, clinical laboratory and local tolerability assessments</measure>
    <time_frame>Up to 48 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LEO 39652 and metabolites in blood</measure>
    <time_frame>Up to 48 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 39652 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 39652 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 39652 cream</intervention_name>
    <arm_group_label>LEO 39652 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cream vehicle</intervention_name>
    <arm_group_label>LEO 39652 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects or subjects with AD as defined by the Hanifen and Rajka criteria and
             with at least mild disease activity (IGA &gt;2) for the whole body

          -  AD lesions amenable to cutaneous treatment located on the trunk and/or limbs (only for
             AD subjects)

          -  Male subjects aged between 18 and 65 years with a body mass index (BMI) between 19.0
             and 32.0 kg/m2 inclusive

        Exclusion Criteria:

          -  Subjects who currently suffer from, or show signs of eczema or other skin lesions
             (only for healthy subjects)

          -  Subjects who are still participating in a clinical trial (e.g. attending follow-up
             visits) or who have participated in a clinical study involving administration of an
             investigational product or a marketed drug product within the past 3 months prior to
             the first dosing occasion.

          -  Subjects with known immunocompromised state due to treatment with immunosuppressive
             drugs or due to history of a disease leading to immunocompromised status.

          -  History of or current cardiac arrhythmic disorder

          -  Subjects with a current active malignancy or a history of malignancy in remission for
             less than 5 years except excised skin (not melanoma) and cervical cancer.

          -  Subjects who have any clinically significant allergic disease (excluding non- active
             hayfever) as determined by the Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Chiesa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Hyde Street, Leeds, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Hyde Street, Leeds, UK</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Royal Liverpool Clinical Research Unit</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

